EXAS Quote, Financials, Valuation and Earnings

Delcath Systems has a net margin of -14.32% compared to Exact Sciences's net margin of 5.4%. Exact Sciences's return on equity of -35.57% beat Delcath Systems's return on equity of -40.28%.

Exact Sciences has a consensus price target of $68.83, signalling upside risk potential of 21.87%. On the other hand Delcath Systems has an analysts' consensus of $23.17 which suggests that it could grow by 43.45%. Given that Delcath Systems has higher upside potential than Exact Sciences, analysts believe Delcath Systems is more attractive than Exact Sciences.

Exact Sciences has a beta of 0.920, which suggesting that the stock is 7.968% less volatile than S&P 500. In comparison Delcath Systems has a beta of 0.722, suggesting its less volatile than the S&P 500 by 27.805%.

Exact Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Delcath Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exact Sciences pays -- of its earnings as a dividend. Delcath Systems pays out -- of its earnings as a dividend.

Exact Sciences quarterly revenues are $706.8M, which are larger than Delcath Systems quarterly revenues of $19.8M. Exact Sciences's net income of -$101.2M is lower than Delcath Systems's net income of $1.1M. Notably, Exact Sciences's price-to-earnings ratio is -- while Delcath Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exact Sciences is 3.70x versus 9.92x for Delcath Systems. Usually stocks with elevated PS ratios are considered overvalued.

Guardant Health has a net margin of -14.32% compared to Exact Sciences's net margin of -46.77%. Exact Sciences's return on equity of -35.57% beat Guardant Health's return on equity of -8518.58%.

Exact Sciences has a consensus price target of $68.83, signalling upside risk potential of 21.87%. On the other hand Guardant Health has an analysts' consensus of $59.55 which suggests that it could grow by 60.72%. Given that Guardant Health has higher upside potential than Exact Sciences, analysts believe Guardant Health is more attractive than Exact Sciences.

Exact Sciences has a beta of 0.920, which suggesting that the stock is 7.968% less volatile than S&P 500. In comparison Guardant Health has a beta of 1.489, suggesting its more volatile than the S&P 500 by 48.904%.

Exact Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Guardant Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exact Sciences pays -- of its earnings as a dividend. Guardant Health pays out -- of its earnings as a dividend.

Exact Sciences quarterly revenues are $706.8M, which are larger than Guardant Health quarterly revenues of $203.5M. Exact Sciences's net income of -$101.2M is lower than Guardant Health's net income of -$95.2M. Notably, Exact Sciences's price-to-earnings ratio is -- while Guardant Health's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exact Sciences is 3.70x versus 5.90x for Guardant Health. Usually stocks with elevated PS ratios are considered overvalued.

Natera has a net margin of -14.32% compared to Exact Sciences's net margin of -13.34%. Exact Sciences's return on equity of -35.57% beat Natera's return on equity of -19.19%.

Exact Sciences has a consensus price target of $68.83, signalling upside risk potential of 21.87%. On the other hand Natera has an analysts' consensus of $191.91 which suggests that it could grow by 25.86%. Given that Natera has higher upside potential than Exact Sciences, analysts believe Natera is more attractive than Exact Sciences.

Exact Sciences has a beta of 0.920, which suggesting that the stock is 7.968% less volatile than S&P 500. In comparison Natera has a beta of 1.794, suggesting its more volatile than the S&P 500 by 79.445%.

Exact Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Natera offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exact Sciences pays -- of its earnings as a dividend. Natera pays out -- of its earnings as a dividend.

Exact Sciences quarterly revenues are $706.8M, which are larger than Natera quarterly revenues of $501.8M. Exact Sciences's net income of -$101.2M is lower than Natera's net income of -$66.9M. Notably, Exact Sciences's price-to-earnings ratio is -- while Natera's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exact Sciences is 3.70x versus 10.68x for Natera. Usually stocks with elevated PS ratios are considered overvalued.

Star Equity Holdings has a net margin of -14.32% compared to Exact Sciences's net margin of -9.1%. Exact Sciences's return on equity of -35.57% beat Star Equity Holdings's return on equity of -15.99%.

Exact Sciences has a consensus price target of $68.83, signalling upside risk potential of 21.87%. On the other hand Star Equity Holdings has an analysts' consensus of $8.50 which suggests that it could grow by 312.62%. Given that Star Equity Holdings has higher upside potential than Exact Sciences, analysts believe Star Equity Holdings is more attractive than Exact Sciences.

Exact Sciences has a beta of 0.920, which suggesting that the stock is 7.968% less volatile than S&P 500. In comparison Star Equity Holdings has a beta of 0.871, suggesting its less volatile than the S&P 500 by 12.92%.

Exact Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Star Equity Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exact Sciences pays -- of its earnings as a dividend. Star Equity Holdings pays out -19.54% of its earnings as a dividend.

Exact Sciences quarterly revenues are $706.8M, which are larger than Star Equity Holdings quarterly revenues of $12.9M. Exact Sciences's net income of -$101.2M is lower than Star Equity Holdings's net income of -$1.2M. Notably, Exact Sciences's price-to-earnings ratio is -- while Star Equity Holdings's PE ratio is 0.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exact Sciences is 3.70x versus 0.11x for Star Equity Holdings. Usually stocks with elevated PS ratios are considered overvalued.